Risk Factors Associated with Suspected Clostridium difficile Infection (CDI) in Elderly Diarrhea Patients at Prof. Dr. I.G.N.G. Ngoerah Hospital
Downloads
Clostridium difficile infection (CDI) is a typical healthcare-associated infection that contributes to a significant proportion of morbidity and mortality among hospitalized patients. Anaerobe microbiological laboratory examinations cannot be performed at Prof. Dr. I.G.N.G. Ngoerah Hospital, leading to many undetected cases; therefore, it is crucial to determine the risk factors. Identification of cases may help to prevent, recognize, and appropriately treat CDI, reducing morbidity and mortality. This study aimed to determine the risk factors associated with suspected CDI in elderly patients with diarrhea due to their vulnerability to immunosenescence. This research used medical records as secondary data to determine the risk factors associated with suspected CDI in elderly diarrhea patients at Prof. Dr. I.G.N.G. Ngoerah Hospital during the year period of 2017 to 2021 with total of 70 samples who met inclusion criteria by purposive sampling technique. One hundred percent of all samples had a history of hospitalization for ³ 48 h. There were 53 patients (77.1%) had a history of antibiotic use, 26 (37.1%) proton pump inhibitors (PPIs), 66 (94.3%) chemotherapy, 66 (94.3%) urinary tract infections, 6 (8.6%) kidney disease, and 7 (10%) myocardial infarction. Seven (10%) patients had vascular disease, and 11 (15.7%) had diabetes mellitus. Risk factors associated with suspected CDI in elderly patients with diarrhea at Prof. Dr. I.G.N.G. Ngoerah Hospital include hospitalization ³ for 48 hours, use of antibiotics in the last few months, proton pump inhibitors, decreased immune system, urinary tract infection, kidney disease, myocardial infarction, vascular disease, and diabetes mellitus.
Kotila SM, Mentula S, Ollgren J, Virolainen-Julkunen A, Lyytikäinen O. Community- and Healthcare-Associated Clostridium difficile Infections, Finland, 2008−2013. Emerging Infectious Disease Journal. 2016;22(10):1747.
Banaei N, Anikst V, Schroeder LF. Burden of Clostridium difficile infection in the United States. The New England Journal of Medicine. 2015;2368–2369.
Czepiel J, Dróżdż M, Pituch H, et al. Clostridium difficile infection: review. European Journal of Clinical Microbiology and Infectious Diseases. 2019;38(7):1211-1221.
Collins DA, Hawkey PM, Riley T V. Epidemiology of Clostridium difficile infection in Asia. Antimicrobial Resistance and Infection Control. 2013;2(1):21.
Putsathit P, Maneerattanaporn M, Piewngam P, Kiratisin P, Riley T V. Prevalence and molecular epidemiology of Clostridium difficile infection in Thailand. New Microbes and New Infections. 2017;15:27–32.
Diniz AN, Moura LNF, Cruz DSG, et al. Characterization of the virulence of three novel clade 2 Clostridioides (Clostridium) difficile strains and a two-year screening in animals and humans in Brazil. PLoS One. 2022;17(8):e0273013.
Nana T, Moore C, Boyles T, et al. South African Society of Clinical Microbiology Clostridioides difficile infection diagnosis, management and infection prevention and control guideline. S Afr J Infect Dis. 2020;35(1):219.
Collins DA, Gasem MH, Habibie TH, Arinton IG, Hendriyanto P, Hartana AP, et al. Prevalence and molecular epidemiology of Clostridium difficile infection in Indonesia. New Microbes and New Infections. 2017;18:34–37.
Rupnik M. Clostridium difficile : (Re)emergence of Zoonotic Potential. Clinical Infectious Diseases. 2010;51(5):583–584.
Azimirad M, Krutova M, Yadegar A, et al. Clostridioides difficile ribotypes 001 and 126 were predominant in Tehran healthcare settings from 2004 to 2018: a 14-year-long cross-sectional study. Emerg Microbes Infect. 2020;9(1):1432-1443.
Nibbering B, Gerding DN, Kuijper EJ, Zwittink RD, Smits WK. Host Immune Responses to Clostridioides difficile: Toxins and Beyond. Front Microbiol. 2021;12:804949.
Engevik MA, Danhof HA, Chang-Graham AL, et al. Human intestinal enteroids as a model of Clostridioides difficile-induced enteritis. Am J Physiol Gastrointest Liver Physiol. 2020;318(5):G870-G888.
Engevik MA, Danhof HA, Chang-Graham AL, et al. Human intestinal enteroids as a model of Clostridioides difficile-induced enteritis. Am J Physiol Gastrointest Liver Physiol. 2020;318(5):G870-G888.
Bagdasarian N, Rao K, Malani PN. Diagnosis and treatment of Clostridium difficile in adults: a systematic review. JAMA. 2015;313(4):398-408.
Vázquez-Cuesta S, Villar L, García NL, et al. Characterization of the gut microbiome of patients with Clostridioides difficile infection, patients with non-C. difficile diarrhea, and C. difficile-colonized patients. Front Cell Infect Microbiol. 2023;13:1130701.
Ventura MT, Cascario M, Gangemi S, Buquicchio R. Immunosenescence in aging: between immune cells depletion and cytokines up-regulation. Clinical and Molecular Allergy. 2017;15(21):1-8.
Fuentes E, Fuentes M, Alarcon M, Palomo I. Immune system dysfunction in the elderly. Annals of the Brazilian Academy of Science. 2017;89(1):285-299.
Magnusson C, Mernelius S, Bengnér M, et al. Characterization of a Clostridioides difficile outbreak caused by PCR ribotype 046, associated with increased mortality. Emerg Microbes Infect. 2022;11(1):850-859.
Magnusson C, Mernelius S, Bengnér M, et al. Characterization of a Clostridioides difficile outbreak caused by PCR ribotype 046, associated with increased mortality. Emerg Microbes Infect. 2022;11(1):850-859.
Ho J, Dai RZW, Kwong TNY, Wang X, Zhang L, Ip M, et al. Disease Burden of Clostridium difficile Infections in Adults, Hong Kong, China, 2006-2014. Emerging Infectious Diseases. 2017;23(10):1671–1679.
Kim YS, Han DS, Kim YH, Kim WH, Kim JS, Kim HS, et al. Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study. Epidemiology and Infection. 2013;141(1):189–194.
Sartelli M, Di Bella S, McFarland LV, et al. 2019 update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg. 2019;14:8.
Hain-Saunders NMR, Knight DR, Bruce M, Riley TV. Clostridioides difficile infection and One Health: an equine perspective. Environ Microbiol. 2022;24(3):985-997.
Jones AM, Kuijper EJ, Wilcox MH. Clostridium difficile: a European perspective. The Journal of Infection. 2013;66(2):115–128.
Cheng JKJ, Unnikrishnan M. Clostridioides difficile infection: traversing host-pathogen interactions in the gut. Microbiology (Reading). 2023;169(2):001306.
Guerrero DM, Nerandzic MM, Jury LA, Jinno S, Chang S, Donskey CJ. Acquisition of spores on gloved hands after contact with the skin of patients with Clostridium difficile infection and with environmental surfaces in their rooms. American Journal of Infection Control. 2012;40(6):556–558.
Asempa TE, Nicolau DP. Clostridium difficile infection in the elderly: an update on management. Clinical Interventions in Aging. 2017;12:1799–1809.
Raeisi H, Azimirad M, Nabavi-Rad A, Asadzadeh Aghdaei H, Yadegar A, Zali MR. Application of recombinant antibodies for treatment of Clostridioides difficile infection: Current status and future perspective. Front Immunol. 2022;13:972930.
Leffler DA, Lamont JT. Clostridium difficile Infection. New England Journal of Medicine. 2015;372(16):1539–1548.
De Roo AC, Regenbogen SE. Clostridium difficile Infection: An Epidemiology Update. Clinics in Colon and Rectal Surgery. 2020;33(2):49-57.
McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1-e48.
Copyright (c) 2023 Indonesian Journal of Tropical and Infectious Disease
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
